Udi Gilboa - 18 Mar 2026 Form 3 Insider Report for Nasus Pharma Ltd (NSRX)

Reporting relationship: Founder & Executive Chairman
Issuer ticker: NSRX
Reported as of: 18 Mar 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 27 Mar 2026, 20:56:43 UTC
Source filing: View source filing
Reporting owner signature: /s/ Udi Gilboa

Key filing fact

Udi Gilboa filed Form 3 for Nasus Pharma Ltd (NSRX) on 27 Mar 2026.

Key facts

This page summarizes Udi Gilboa's Form 3 filing for Nasus Pharma Ltd (NSRX).
0 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 27 Mar 2026, 20:56.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001599094 Primary reporting owner

Gilboa Udi

Relationship: Founder & Executive Chairman
Address: P.O. BOX 284, TEL-AVIV-YAFO, ISRAEL
Signature: /s/ Udi Gilboa
Signature date: 27 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NSRX holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,919,281
Date: 18 Mar 2026
Ownership: Direct

NSRX holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 5,195
Date: 18 Mar 2026
Ownership: By Formulex Pharma Innovations Ltd.
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NSRX holding Derivative

Warrants

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 18 Mar 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 17,970
Exercise price: $6.53
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents ordinary shares of the Issuer, no par value ("Ordinary Shares") directly held by Formulex Pharma Innovations Ltd. ("Formulex"). Mr. Udi Gilboa, as a beneficial owner of Formulex, may be deemed to beneficially own the Ordinary Shares owned directly by Formulex.

Footnote F2

The warrants to purchase up to 17,970 Ordinary Shares (the "Warrants") were issued on February 13, 2026. The Warrants have an exercise price of $6.53 per share, were immediately exercisable, and will expire upon the earlier of two years from the date of issuance and 30 trading days following the Issuer's announcement of the top-line results of the Issuer's NS002 Pivotal Study.